Mitochondria in situ releasing corosolic acid enhanced antitumor effects via activating mitophagy in castration-resistant prostate cancer
Ontology highlight
ABSTRACT: Corosolic acid (CA) and its derivatives constitute a prominent class of drug candidates; however, their anticancer efficacy against resistant cancer types has been infrequently documented. Organelle-targeted drug delivery is a promising strategy to maximize anti-cancer effects and minimize adverse reactions. Herein, we report a mitochondria-targeted prodrug (CA-TPP) via an esterase-responsive phenolic ester bond to in situ release enough original drug (corosolic acid, CA) in mitochondria, and enhance the therapeutic efficacy. This mitochondria in situ releasing original drug theragnosis significantly reduced the treatment dose of CA to 25% both in vivo and in vitro. CA-TPP induces cell death in DU145 cells through mitochondrial-apoptosis pathway. RNA sequencing analysis further revealed that CA-TPP activated apoptosis through PINK1/Parkin-mediated mitophagy. Inhibition of mitophagy by PINK1 shRNA resulted in an alleviation in CA-TPP induced cytotoxicity in DU145 cells. Further mechanistic study indicates that ROS production in CA-TPP-treated cells causes mitochondrial apoptosis and mitophagy. Together, this prodrug design strategy obviously improved the specificity and anti-tumor activities, which provides a novel opportunity for cancer therapeutic development and broaden the targeted therapy options.
ORGANISM(S): Homo sapiens
PROVIDER: GSE315376 | GEO | 2026/05/15
REPOSITORIES: GEO
ACCESS DATA